Participants may not have a major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to starting cediranib; anticipation of need for major surgical procedures during the course of the study also excludes patients from the trialXx_NEWLINE_xXPatients who have had or are planning to have the following invasive procedures are not eligible:\r\n* Major surgical procedure, laparoscopic procedure, open biopsy or significant traumatic injury within 28 days prior to enrollment\r\n* Subcutaneous port placement or central line placement is not considered major surgery; external central lines must be placed at least 3 days prior to enrollment and subcutaneous ports must be placed at least 7 days prior to enrollment\r\n* Core biopsy within 7 days prior to enrollment\r\n* Fine needle aspirate within 7 days prior to enrollment\r\n* NOTE: For purposes of this study, bone marrow aspirate and biopsy are not considered surgical procedures and therefore are permitted within 14 days prior to start of protocol therapyXx_NEWLINE_xXMajor surgical procedure (including open biopsy, significant traumatic injury, etc.) within 28 days, or anticipation of the need for major surgical procedure during the course of the study as well as minor surgical procedure (excluding placement of a vascular access device or bone marrow biopsy) within 7 days prior to study enrollmentXx_NEWLINE_xXAn open biopsy, non-healing wound, ulcer or significant traumatic injury within 28 days prior to starting treatment (percutaneous, endobronchial, and endoscopic biopsies are allowed)Xx_NEWLINE_xXMajor surgical procedure or significant traumatic injury within 4 weeks prior to randomization and must have fully recovered from any such procedure or injury; planned surgery (if applicable) or the anticipated need for a major surgical procedure within the next six months. Note: the following are not considered to be major procedures and are permitted up to 7 days before randomization: Thoracentesis, paracentesis, port placement, laparoscopy, thoracoscopy, tube thoracostomy, bronchoscopy, endoscopic ultrasonographic procedures, mediastinoscopy, skin biopsies, and imaging-guided biopsy for diagnostic purposesXx_NEWLINE_xXMajor surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to randomization or anticipation of need for a major surgical procedure during the course of the studyXx_NEWLINE_xXPatients who have had significant traumatic injury within 28 days prior to enrollment are not eligibleXx_NEWLINE_xXNo major surgical procedure or significant traumatic injury within 6 weeks prior to study registration, and must have fully recovered from any such procedure.Xx_NEWLINE_xXSignificant traumatic injury within 3 weeks prior to planned initiation of study therapyXx_NEWLINE_xXMajor surgery, open biopsy or significant traumatic injury within 4 weeks prior to study entryXx_NEWLINE_xXMajor surgical procedure or significant traumatic injury within 28 days prior to study enrollmentXx_NEWLINE_xXMajor surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to day 1 of treatment or anticipation of need for major surgical procedure during the course of the studyXx_NEWLINE_xXTraumatic injury within 2 weeks before initiation of study treatmentXx_NEWLINE_xXPatients who have had or are planning to have the following invasive procedures will be excluded:\r\n* Major surgical procedures, laparoscopic procedure, open biopsy, or significant traumatic injury within 28 days prior to day 1 therapy; subcutaneous port placement or central line placement is not considered major surgery, but must be placed greater than 48 hours from planned day 1 of therapy\r\n* Core biopsy within 7 days prior to day 1 therapy\r\n* Fine needle aspirate or central line placement within 48 hours prior to day 1 therapy\r\nNote: Routine bone marrow aspirate and biopsy for the purposes of disease staging are not part of these exclusion guidelinesXx_NEWLINE_xXMajor surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to enrollment, or anticipation of need for major surgical procedure during the course of the studyXx_NEWLINE_xXPatients who have undergone major surgery (ie, intra-thoracic, intra abdominal or intra-pelvic), open biopsy or significant traumatic injury =< 4 weeks prior to starting study drug, or patients who have had minor procedures, percutaneous biopsies or placement of vascular access device =< 1 week prior to starting study drug, or who have not recovered from side effects of previous procedure or injuryXx_NEWLINE_xXMajor surgery or significant traumatic injury within 14 days prior to therapyXx_NEWLINE_xXMajor surgical procedure or significant traumatic injury within 28 days before start of study registrationXx_NEWLINE_xXMajor surgical procedure, open biopsy, or significant traumatic injury within 28 days before start of study medicationXx_NEWLINE_xXPrior therapy:\r\n* Prior treatment with systemic immunosuppressive treatments, aside from systemic dexamethasone therapy for cerebral edema, such as methotrexate, chloroquine, azathioprine, etc. within 3 months of start of study therapy\r\n* Prior treatment with interstitial brachytherapy within 6 months of start of study therapy\r\n* Previous treatment with programmed death-protein 1 (PD-1) or programmed death-ligand 1 (PD-L1) directed therapy\r\n* Surgical procedure (including open biopsy, surgical resection, wound revision, or any other major surgery involving entry into a body cavity) or significant traumatic injury within 28 days prior to first study treatment, or anticipation of need for major surgical procedure during the course of the study\r\n* Minor surgical procedure (eg, stereotactic biopsy within 7 days of first study treatment; placement of a vascular access device within 2 days of first study treatment)Xx_NEWLINE_xXMajor surgery or significant traumatic injury <28 days prior to the first RO6874281 infusion (excluding biopsies) or anticipation of the need for major surgery during study treatmentXx_NEWLINE_xXMajor surgical procedure or significant traumatic injury within 14 days of initiating study drug or anticipation of the need for major surgery during the studyXx_NEWLINE_xXPatients may have undergone a major or minor surgical procedure as long as the following apply:\r\n* Major surgical procedure, open biopsy or significant traumatic injury greater than 28 days prior to the first date of study therapy\r\n* Core biopsy or intravenous (IV) port placement greater than 7 days prior to the first date of study therapyXx_NEWLINE_xXPatients who have had a major surgery or significant traumatic injury within 2 weeks of start of study drugXx_NEWLINE_xXMajor surgical procedure or significant traumatic injury within 28 days prior to study entry or anticipation of the need for major surgery during the course of study treatmentXx_NEWLINE_xXMajor surgical procedure or significant traumatic injury within 14 days of initiating study drug or anticipation of the need for major surgery during the studyXx_NEWLINE_xXMajor surgery or significant traumatic injury <28 days prior to Cycle 1 Day 1 (excluding fine needle biopsies) or anticipation of the need for major surgery during study treatmentXx_NEWLINE_xXPatients who have had or are planning to have the following invasive procedures will be excluded- Major surgical procedure, laparoscopic procedure, open biopsy or significant traumatic injury within 28 days prior to Day 1 therapy (Subcutaneous port placement or central line placement is not considered major surgery but must be placed greater than 48 hours from planned Day 1 of therapy); Core biopsy within 7 days prior to Day 1 therapy; Fine needle aspirate or central line placement within 48 hours prior to Day 1therapy.Xx_NEWLINE_xXPatients who have had or are planning to have the following invasive procedures are not eligible:\r\n* Major surgical procedure, laparoscopic procedure, open biopsy or significant traumatic injury within 28 days prior to enrollment\r\n* Central line placement or subcutaneous port placement is not considered major surgery; external central lines must be placed at least 3 days prior to enrollment and subcutaneous ports must be placed at least 7 days prior to enrollment\r\n* Core biopsy within 7 days prior to enrollment\r\n* Fine needle aspirate within 7 days prior to enrollment\r\n* Surgical or other wounds must be adequately healed prior to enrollment; Note: for purposes of this study, bone marrow aspirate and biopsy are not considered surgical procedures and therefore are permitted within 14 days prior to start of protocol therapyXx_NEWLINE_xXMajor surgical procedure (including open biopsy, significant traumatic injury, etc.) within 28 days, or anticipation of the need for major surgical procedure during the course of the study as well as minor surgical procedure (excluding placement of a vascular access device or bone marrow biopsy) within 7 days prior to randomization.Xx_NEWLINE_xXMajor surgical procedure or significant traumatic injury within 28 days prior to Day 1, Cycle 1, or anticipation of the need for major surgery during study treatmentXx_NEWLINE_xXMajor surgery or significant traumatic injury within 60 days prior to enrollmentXx_NEWLINE_xXMajor surgical procedure, open biopsy, or significant traumatic injury within 28 days before start of study medicationXx_NEWLINE_xXMajor surgical procedure, open biopsy, or significant traumatic injury within 28 days before start of study medicationXx_NEWLINE_xXMajor surgery or significant traumatic injury less than (<) 28 days prior to the first cergutuzumab amunaleukin infusion (excluding biopsies) or anticipation of the need for major surgery during study treatmentXx_NEWLINE_xXMajor surgical procedure, open biopsy, or significant traumatic injury within 30 days prior to Cycle 1, Day 1 or anticipation of need for major surgical procedure during the course of the studyXx_NEWLINE_xXPatients who have had major surgical procedures or significant traumatic injury within 28 days prior to study treatmentXx_NEWLINE_xXPatients who have undergone major surgery (e.g. intra-thoracic, intra-abdominal or intra-pelvic), open biopsy or significant traumatic injury =< 4 weeks prior to starting study drug, or patients who have had minor procedures, percutaneous biopsies or placement of vascular access device =< 1 week prior to starting study drug, or who have not recovered from side effects of such procedure or injuryXx_NEWLINE_xXPatients who have undergone major surgery (e.g. intra-thoracic, intra-abdominal or intra-pelvic), open biopsy or significant traumatic injury =< 4 weeks prior to starting study drug, or patients who have had minor procedures (i.e. TURBT), percutaneous biopsies or placement of vascular access device =< 1 week prior to starting study drug, or who have not recovered from side effects of such procedure or injuryXx_NEWLINE_xXMajor surgery, open biopsy, significant traumatic injury within 28 days of starting treatment or anticipation of need for major surgical procedure during the course of the studyXx_NEWLINE_xXInvasive procedures defined as follows:\r\n* Major surgical procedure or significant traumatic injury within 28 days prior to day 1 therapy, or open biopsy within 7 days prior to day 1 therapy\r\n* Anticipation of need for major surgical procedures during the course of the studyXx_NEWLINE_xX=< 28 days before first dose of protocol-indicated treatment:\r\n* Anti-cancer treatment with bevacizumab.\r\n* Major surgery requiring general anesthesia or significant traumatic injury.Xx_NEWLINE_xXMajor surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to day 1 or anticipation of need for major surgical procedure during the course of the studyXx_NEWLINE_xXPatients who have had a major surgical procedure within 14 days of randomization. Patient has significant traumatic injury within 28 days before randomization.Xx_NEWLINE_xXSurgical procedure (including open biopsy, surgical resection, wound revision, or any other major surgery involving entry into a body cavity) or significant traumatic injury within 28 days prior to first study treatment, or anticipation of need for major surgical procedure during the course of the study.Xx_NEWLINE_xXMajor surgery or significant traumatic injury greater than or equal to 28 days prior to the first LMB-100 infusion (excluding biopsies) or anticipation of the need for major surgery during study treatmentXx_NEWLINE_xXHad major surgical procedure, open biopsy, or significant traumatic injury within 21 days prior to day 1 of treatment on studyXx_NEWLINE_xXPatients must have fully recovered from the effects of any major surgery or significant traumatic injury within 14 days of course 1 day 1 (C1D1)Xx_NEWLINE_xXSubjects must have recovered from the effects of major surgery or significant traumatic injury at least 14 days before first treatmentXx_NEWLINE_xXA major surgical procedure, open biopsy, or significant traumatic injury within 3 months prior to cycle 1 day 1 (percutaneous/endobronchial/endoscopic biopsies are allowed)Xx_NEWLINE_xXStem cell infusion without traumatic brain injuryXx_NEWLINE_xXMajor surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to the start of study drug (56 days for hepatectomy, open thoracotomy, major neurosurgery) or anticipation of need for major surgical procedure during the course of the study (except for the planned metastasectomy)Xx_NEWLINE_xXParticipants must have recovered from the effects of major surgery requiring general anesthesia or significant traumatic injury at least 14 days before treatment arm assignmentXx_NEWLINE_xXMajor surgical procedure (including craniotomy and open brain biopsy) or significant traumatic injury within 14 days prior to registration or those patients who receive a non-central nervous system (CNS) minor surgical procedures (e.g. core biopsy or fine needle aspiration) within 3 days prior to registration; there is no waiting period for central line placement; there is a 7-day window for recovery prior to registration for patients who underwent stereotactic biopsy of the brainXx_NEWLINE_xXPatients with a major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to initiation of therapy, or anticipation of need for major surgical procedure during the course of the study other than that defined by protocol are ineligibleXx_NEWLINE_xXMajor surgery or significant traumatic injury within 14 days prior to Cycle 1 Day 1Xx_NEWLINE_xXMajor surgical procedure or significant traumatic injury within 28 days prior to day 1 or anticipation of the need for major surgery during the course of study treatmentXx_NEWLINE_xXSerious non-healing wound, ulcer, bone fracture, major surgical procedure, open biopsy or significant traumatic injury within 28 days prior to “on-study” statusXx_NEWLINE_xXSubjects who have not recovered from the effects of major surgery or significant traumatic injury at least 14 days before the first dose of study treatment.Xx_NEWLINE_xXMajor surgical procedure or significant traumatic injury within 28 days prior to study drug administration.Xx_NEWLINE_xXPatients who have had a major surgical procedure, open biopsy, or significant traumatic injury with poorly healed wound within 6 weeks prior to first dose of study drug; or anticipation of need for major surgical procedure during the course of the study (other than defined by protocol); or fine needle aspirations or core biopsies) within 7 days prior to first dose of study drug. NOTE: Patients will be allowed to start cycle 1 day 1 therapy after 24 hours from pre-treatment biopsyXx_NEWLINE_xXMajor surgical procedure with 4 weeks of first dose of study drug; open biopsy, or significant traumatic injury within 7 days prior to enrollment date; anticipation of need for major surgical procedure during the course of the study.Xx_NEWLINE_xXRecovery from effects of any major surgery or significant traumatic injury at least 28 days before the first dose of study treatmentXx_NEWLINE_xXMajor surgical procedure or significant traumatic injury within 4 weeks prior to study treatment, and must have fully recovered from any such procedure; and no date of surgery (if applicable) or anticipated need for a major surgical procedure planned within the next 6 months (Note: The following are not considered to be major procedures and are permitted up to 7 days prior to study treatment: Thoracentesis, paracentesis, port placement, laparoscopy, thorascopy, tube thoracostomy, bronchoscopy, endoscopic ultrasonographic procedures, mediastinoscopy, skin biopsies, incisional biopsies, imaging-guided biopsy for diagnostic purposes, and routine dental procedures.)Xx_NEWLINE_xX(Bevacizumab-related exclusion) Surgical procedure (including open biopsy, surgical resection, wound revision, or any other major surgery involving entry into a body cavity) or significant traumatic injury within 28 days prior to study enrollment, or anticipation of need for major surgical procedure during the course of the study. For patients with brain tumors, craniotomy or intracranial biopsy sites must be adequately healed; free of drainage or cellulitis, and the underlying cranioplasty must appear intact at the time of study enrollmentXx_NEWLINE_xXFOR ALL PHASES (Ib AND II): Major surgical procedure or significant traumatic injury (as judged by the investigator) within 28 days before start of study medication, open biopsy within 7 days before start of study medicationXx_NEWLINE_xXSubjects must have recovered from the effects of major surgery or significant traumatic injury at least 14 days before registrationXx_NEWLINE_xXMajor surgical procedure or significant traumatic injury within 28 days before start of study medicationXx_NEWLINE_xXMajor surgical procedure, open biopsy, or significant traumatic injury within 28 days of day 1 of therapy.Xx_NEWLINE_xXMajor surgical procedure or significant traumatic injury within 28 days before start of study medicationXx_NEWLINE_xXMajor surgery or significant traumatic injury occurring within 21 days prior to treatmentXx_NEWLINE_xXMajor surgery, open biopsy or significant traumatic injury within 28 days before the start of study treatmentXx_NEWLINE_xXA major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to starting cediranib (percutaneous/endobronchial biopsies are allowed)Xx_NEWLINE_xXPatients, who have had a major surgery or significant traumatic injury (injury requiring > 4 weeks [28 days] to heal) within 4 weeks (28 days) of start of study drug, patients who have not recovered from the side effects of any major surgery (defined as requiring general anesthesia) or patients that are expected to require major surgery during the course of the studyXx_NEWLINE_xXPatients who have undergone major surgery (e.g. intra-thoracic, intra- abdominal or intra-pelvic), open biopsy or significant traumatic injury ? 4 weeks prior to starting study drug, or patients who have had minor procedures (i.e. transurethral resection of bladder tumor [TURBT]), percutaneous biopsies or placement of vascular access device ? 1 week prior to starting study drug, or who have not recovered from side effects of such procedure or injuryXx_NEWLINE_xXMajor surgical procedure, open biopsy or significant traumatic injury =< 28 days prior to registrationXx_NEWLINE_xXMajor surgery or significant traumatic injury =< 28 days prior to the first LMB-100 infusion (excluding biopsies) or anticipation of the need for major surgery during study treatmentXx_NEWLINE_xXOr a traumatic brain injury will be excludedXx_NEWLINE_xXPatients who have had or are planning to have the following invasive procedures are not eligible:\r\n* Major surgical procedure, laparoscopic procedure, open biopsy or significant traumatic injury within 14 days prior to initiation of protocol therapy; there should be no anticipation of need for major surgical procedures during the course of the study\r\n* Central line placement or subcutaneous port placement is not considered major surgery; external central lines must be placed at least 3 days prior to initiation of protocol therapy and subcutaneous ports must be placed at least 7 prior to initiation of protocol therapyXx_NEWLINE_xXMajor surgery or significant traumatic injury within 2 weeks of run-inXx_NEWLINE_xXMajor surgical procedure, open biopsy, or significant traumatic injury within 28 days of day 1 of therapyXx_NEWLINE_xXA minimum time period must elapse between the end of a previous treatment and start of study therapy:\r\n* 1 week from the completion of radiation therapy for brain metastases\r\n* 4 weeks from the completion of chemotherapy or any experimental therapy\r\n* 4 weeks from prior major surgery (such as open biopsy or significant traumatic injury)Xx_NEWLINE_xXSurgical procedure (including open biopsy, surgical resection, wound revision, or any other major surgery involving entry into a body cavity) or significant traumatic injury within 28 days prior to on-study date, or anticipation of need for major surgical procedure during the course of the studyXx_NEWLINE_xXMajor surgical procedure or significant traumatic injury within 14 days prior to first dose of study drug treatment on Study Day 1 of Period A, or anticipation of the need for major surgery during study treatmentXx_NEWLINE_xXREGORAFENIB EXCLUSION CRITERIA: Major surgical procedure or significant traumatic injury within 28 days before start of regorafenibXx_NEWLINE_xXInvasive surgical intervention (including biopsy by surgical route), major traumatic injury during the 28 days prior to the start of treatment, or scheduled invasive surgical intervention during the study treatmentXx_NEWLINE_xXMajor surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to day 0, anticipation of need for major surgical procedure during the course of the study; as an example, port placement or core biopsies are not considered major surgical proceduresXx_NEWLINE_xXMajor surgery, open biopsy or significant traumatic injury within 4 weeks of first study drugXx_NEWLINE_xXMajor surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to starting cediranibXx_NEWLINE_xXNo major surgical procedure or significant traumatic injury within 6 weeks prior to study registration, and must have fully recovered from any such procedure; date of surgery (if applicable) or the anticipated need for a major surgical procedure within the next six months; Note: the following are not considered to be major procedures and are permitted up to 7 days before therapy initiation: thoracentesis, paracentesis, port placement, laparoscopy, thoracoscopy, tube thoracostomy, bronchoscopy, endoscopic ultrasonographic procedures, mediastinoscopy, skin biopsies, incisional biopsies, imaging-guided biopsy for diagnostic purposes, and routine dental proceduresXx_NEWLINE_xXMajor surgery or significant traumatic injury occurring within 21 days prior to treatmentXx_NEWLINE_xXPatients who have undergone major surgery (e.g. intra-thoracic, intra-abdominal or intra-pelvic), open biopsy or significant traumatic injury =< 4 weeks prior to starting study drug, or patients who have had minor procedures, percutaneous biopsies or placement of vascular access device =< 1 week prior to starting study drug, or who have not recovered from side effects of such procedure or injuryXx_NEWLINE_xXPatients who have had a major surgical procedure, open biopsy, or significant traumatic injury with poorly healed wound within 6 weeks prior to first dose of study drug; or anticipation of need for major surgical procedure during the course of the study (other than defined by protocol); or fine needle aspirations or core biopsies within 7 days prior to first dose of study drugXx_NEWLINE_xXMajor surgical procedure, open biopsy, or significant traumatic injury within 14 days prior to day 1 or anticipation of need for major non-cranial surgical procedure during the course of the studyXx_NEWLINE_xXSignificant traumatic injury within the past 4 weeks.Xx_NEWLINE_xXMinimum interval since last major surgery (e.g. intra-thoracic, intra-abdominal or intra-pelvic), open biopsy, or significant traumatic injury is 4 weeks prior to registration; minimum interval since minor procedures, percutaneous biopsies or placement of vascular access device is 1 week prior to registration; patients must have recovered from side effects of such procedure or injury prior to registrationXx_NEWLINE_xXMajor surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to day 0, anticipation of need for major surgical procedure during the course of the studyXx_NEWLINE_xXSurgery (including open biopsy), significant traumatic injury within 28 days prior to randomization, minor surgery, including insertion of an indwelling catheter, within 24 hours prior to the first bevacizumab infusion is allowedXx_NEWLINE_xXMajor surgery, open biopsy or significant traumatic injury within 4 weeks of first study drugXx_NEWLINE_xXInvasive procedures defined as follows:\r\n* Major surgical procedure, open biopsy or significant traumatic injury within 28 days prior to day 1 therapy\r\n* Anticipation of need for major surgical procedures during the course of the study\r\n* Core biopsy within 7 days prior to day 1 (D1) therapyXx_NEWLINE_xXMajor surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to day 1 of FOLFIRI + bevacizumab initiation or anticipation of need for major surgical procedure during the course of the studyXx_NEWLINE_xXMajor surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to day 1 of study drug (56 days for hepatectomy, open thoracotomy, major neurosurgery) or anticipation of need for major surgical procedure during the course of the studyXx_NEWLINE_xXMajor surgical procedure or significant traumatic injury within 28 days prior to study drug administrationXx_NEWLINE_xXMajor surgery or significant traumatic injury within 4 weeks of starting study treatment.Xx_NEWLINE_xXMajor surgery or significant traumatic injury within 4 weeks of starting study treatment.Xx_NEWLINE_xXSubjects must have recovered from the effects of major surgery requiring general anesthetic or significant traumatic injury at least 14 days before Study Day 0.Xx_NEWLINE_xXMajor surgical procedure or significant traumatic injury within 28 days before the first dose of study drug or anticipation of the need for major surgery during the course of study treatment.Xx_NEWLINE_xXSurgery (including open biopsy), significant traumatic injury within 28 days prior to randomization, or anticipation of the need for major surgery during study treatmentXx_NEWLINE_xXMajor surgery or significant traumatic injury that is not recovered at least 14 days before the initiation of thoracic radiation therapyXx_NEWLINE_xXHad major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to day 1 of treatment on studyXx_NEWLINE_xXSerious non-healing wound, ulcer, bone fracture, major surgical procedure, open biopsy or significant traumatic injury within 28 days prior to being registered for protocol therapyXx_NEWLINE_xXMajor surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to starting cediranibXx_NEWLINE_xXMajor surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 1 or anticipation of need for major surgical procedure during the course of the studyXx_NEWLINE_xXMajor surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to registration (biliary stenting or percutaneous biliary drainage are not included)Xx_NEWLINE_xXMajor surgical procedure, open biopsy, or significant traumatic injury less than 3 weeks or those who receive minor surgical procedures (eg core biopsy or fine needle aspiration) within 1 week from first dose of first study drug administrationXx_NEWLINE_xXPatients who have had or are planning to have the following invasive procedures are not eligible:  \r\n* Major surgical procedure, laparoscopic procedure, open biopsy or significant traumatic injury within 28 days prior to enrollment\r\n* Central line placement or subcutaneous port placement is not considered major surgery but must be placed at least 3 days prior to enrollment for external lines (e.g. Hickman or Broviac) and at least 7 days prior to enrollment for subcutaneous port\r\n* Core biopsy within 7 days prior to enrollment\r\n* Fine needle aspirate within 7 days prior to enrollment\r\n* NOTE: for purposes of this study, bone marrow aspirate and biopsy are not considered surgical procedures and therefore are permitted within 14 days prior to start of protocol therapyXx_NEWLINE_xXPatients who have had or are planning to have the following invasive procedures are not eligible:\r\n* Major surgical procedure, laparoscopic procedure, open biopsy or significant traumatic injury within 28 days prior to enrollment\r\n* Subcutaneous port placement or central line placement is not considered major surgery; external central lines must be placed at least 3 days prior to enrollment and subcutaneous ports must be placed at least 7 days prior to enrollment\r\n* Core biopsy within 7 days prior to enrollment\r\n* Fine needle aspirate within 7 days prior to enrollment\r\n* NOTE: for purposes of this study, bone marrow aspirate and biopsy are not considered surgical procedures and therefore are permitted within 14 days prior to start of protocol therapyXx_NEWLINE_xXInvasive procedures defined as follows:\r\n* Major surgical procedure, open biopsy or significant traumatic injury within 28 days prior to day 1 therapy\r\n* Anticipation of need for major surgical procedures during the course of the study\r\n* Core biopsy within 7 days prior to day 1 therapyXx_NEWLINE_xXPatients who have a major surgical procedure, or significant traumatic injury within 28 days prior to the first date of treatment on this study, or anticipation of need for major surgical procedure during the course of the study; patients with placement of vascular access device or core biopsy within 7 days prior to the first date of treatment on this studyXx_NEWLINE_xXMajor surgery or significant traumatic injury within 4 weeks of first study drugXx_NEWLINE_xXPatients with invasive procedures or anticipation of invasive procedures within the following timeframes as defined below:\r\n* Major surgical procedure, open biopsy or significant traumatic injury within 28 days prior to the first date of bevacizumab therapy (cycle 2)\r\n* Major surgical procedure anticipated during the course of the study\r\n* Core biopsy within 7 days prior to the first date of bevacizumab therapy (cycle 2)Xx_NEWLINE_xXMajor surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to study enrollment or anticipation of need for major surgical procedure during the course of the studyXx_NEWLINE_xXMajor surgical procedure, open biopsy or significant traumatic injury within 28 days prior to randomization on this studyXx_NEWLINE_xXThis criterion applies only to the patients enrolled before August 29, 2011 and those enrolled after this date electing to receive bevacizumab; patients who have had a major surgical procedure, open biopsy, dental extractions or other dental surgery/procedure that results in an open wound, or significant traumatic injury within 28 days prior to the first date of treatment on this study, or anticipation of need for major surgical procedure during the course of the study; patients with placement of vascular access device or core biopsy within 7 days prior to the first date of treatment on this studyXx_NEWLINE_xXCraniotomy or any other major surgery, open biopsy, or significant traumatic injury within 4 weeks of enrollmentXx_NEWLINE_xXMajor surgery, open biopsy or significant traumatic injury within 28 days prior to randomization, or anticipation of the need for major surgery during the course of study treatment.Xx_NEWLINE_xXPatients who have had a major surgery or significant traumatic injury within 4 weeks from day 1 of study drugXx_NEWLINE_xXNo major surgical procedure or significant traumatic injury within 6 weeks prior to study registration, and must have fully recovered from any such procedure; date of surgery (if applicable). Note: the following are not considered to be major procedures and are permitted up to 7 days before therapy initiation: Thoracentesis, paracentesis, port placement, laparoscopy, thorascopy, tube thoracostomy, bronchoscopy, endoscopic ultrasonographic procedures, mediastinoscopy, skin biopsies, incisional biopsies, imaging-guided biopsy for diagnostic purposes, and routine dental proceduresXx_NEWLINE_xXNo major surgical procedures, open biopsy or significant traumatic injury =< 28 days prior to registration or anticipation of need for elective or planned major surgical procedure during the study; core biopsy or other minor surgical procedures =< 7 days prior to registrationXx_NEWLINE_xXMajor surgical procedure or significant traumatic injury within 28 days prior to randomization or anticipation of the need for major surgery during the course of study treatmentXx_NEWLINE_xXPatients are excluded if they have had a surgical procedure or a significant traumatic injury within 28 days prior to randomizationXx_NEWLINE_xXMajor surgery or significant traumatic injury within 4 weeks prior to study entry.Xx_NEWLINE_xXMajor surgery (including ostomy reversal), open biopsy or significant trauma injury, within 28 days prior to randomization.Xx_NEWLINE_xXMajor surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to day 0, or anticipated need for major surgical procedure during the course of the study, or fine needle aspirations or core biopsies within 7 days prior to day 0Xx_NEWLINE_xXundergone major surgery or suffered from significant traumatic injuryXx_NEWLINE_xXMajor surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 1 or anticipation of need for major surgical procedure during course of the study.Xx_NEWLINE_xXMajor surgical procedure, open biopsy, or significant traumatic injury within 28 days before start of study medicationXx_NEWLINE_xXNo major surgical procedure or significant traumatic injury within 6 weeks prior to study registration, and must have fully recovered from any such procedure; date of surgery (if applicable). Note: the following are not considered to be major procedures and are permitted up to 7 days before therapy initiation: Thoracentesis, paracentesis, port placement, laparoscopy, thorascopy, tube thoracostomy, bronchoscopy, endoscopic ultrasonographic procedures, mediastinoscopy, skin biopsies, incisional biopsies, imaging-guided biopsy for diagnostic purposes, and routine dental proceduresXx_NEWLINE_xXMajor surgery, open biopsy or significant traumatic injury within 4 weeks of first study drugXx_NEWLINE_xXMajor surgery, or significant traumatic injury occurring within 21 days prior to treatmentXx_NEWLINE_xXSurgical procedure (including open biopsy, surgical resection, wound revision, or any other major surgery involving entry into a body cavity) or significant traumatic injury within 28 days prior to study enrollment, or anticipation of need for major surgical procedure during the course of the study; minor surgical procedures including placement of a vascular access device, within 2 days of the first study treatmentXx_NEWLINE_xXhave experienced any of the following: a major surgical procedure, significant traumatic injury, non-healing wound, peptic ulcer, or bone fracture less than or equal to 28 days prior to enrollment, or placement of a subcutaneous venous access device less than or equal to 7 days prior to the first dose of study treatment unless the procedure is of low risk of bleeding in the judgment of the investigatorXx_NEWLINE_xXHave had a major surgical procedure or significant traumatic injury including nonhealing wound, peptic ulcer, or bone fracture ?28 days prior to randomization.Xx_NEWLINE_xXMajor surgical procedure, open biopsy, or significant traumatic injury within 28 days before start of study medication.Xx_NEWLINE_xXHad major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to day 1 of treatment on studyXx_NEWLINE_xXMajor surgery or significant traumatic injury within 8 weeks of first study drug; a core pancreatic or liver biopsy does not preclude the patient from the studyXx_NEWLINE_xXMajor surgical procedure, open biopsy, or significant traumatic injury within 30 days prior to Cycle 1, Day 1 or anticipation of need for a major surgical procedure during the course of the studyXx_NEWLINE_xXParticipants must have recovered from effects of any major surgery or significant traumatic injury at least 28 days before the first dose of study treatmentXx_NEWLINE_xXMajor surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to enrollment date, anticipation of need for major surgical procedure during the course of the studyXx_NEWLINE_xXFully recovered from the effects of any major surgery or significant traumatic injury prior to the first dose of study treatmentXx_NEWLINE_xXMajor surgical procedure or significant traumatic injury within 4 weeks prior to first dose of study treatmentXx_NEWLINE_xXSubject has undergone a major surgical procedure, open biopsy, radiofrequency ablation or has experienced a significant injury within 28 days prior to enrollmentXx_NEWLINE_xXMajor surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 0, anticipation of need for major surgical procedure during the course of the study; minor surgical procedures such as fine needle aspirations or core biopsies within 7 days prior to Day 0Xx_NEWLINE_xXMajor surgical procedure, open biopsy, or significant traumatic injury =< 28 days prior to registration (=< 56 days for hepatectomy, open thoracotomy, major neurosurgery) or anticipation of need for major surgical procedure during the course of the studyXx_NEWLINE_xXMajor surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to starting nivolumab and bevacizumabXx_NEWLINE_xXMajor surgical procedure, open biopsy, or significant traumatic injury =< 56 days prior to randomizationXx_NEWLINE_xXMajor surgical procedure, open biopsy, or significant traumatic injury within 28 days before start of study medicationXx_NEWLINE_xXSubjects who have not recovered from the effects of major surgery or significant traumatic injury at least 14 days before the first dose of study treatmentXx_NEWLINE_xXMajor surgical procedure, open biopsy, or significant traumatic injury =< 28 days prior to randomizationXx_NEWLINE_xXParticipants may not have a major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to starting cediranibXx_NEWLINE_xXPatients who have a major surgical procedure, or significant traumatic injury within 28 days prior to the first date of treatment on this study, or anticipation of need for major surgical procedure during the course of the study; patients with placement of vascular access device or core biopsy within 7 days prior to the first date of treatment on this studyXx_NEWLINE_xXMajor surgery, or significant traumatic injury within 4 weeks prior to study entryXx_NEWLINE_xXMajor surgical procedure, open biopsy, or significant traumatic injury =< 4 weeks prior to registration/randomization; (port-a-cath placement does not count as a major surgical procedure and patients can be enrolled at any time after placement)Xx_NEWLINE_xXMajor surgical procedure, open biopsy, or significant traumatic injury within 28 days before start of study medicationXx_NEWLINE_xXMajor surgery, open biopsy or significant traumatic injury within 2 weeks of first dose of study drugXx_NEWLINE_xXMajor surgical procedure, open biopsy, or significant traumatic injury within 28 days before start of study medicationXx_NEWLINE_xXMajor surgery or significant traumatic injury within 4 weeks of starting study treatment.Xx_NEWLINE_xXMajor surgery or significant traumatic injury within 4 weeks of first study drugXx_NEWLINE_xXhistory of traumatic brain or head injury with loss of consciousnessXx_NEWLINE_xXMajor surgical procedure, laparoscopic procedure, open biopsy or significant traumatic injury within 28 days prior to enrollmentXx_NEWLINE_xXMajor surgery, open biopsy or significant traumatic injury within 4 weeks of first dose of study drugXx_NEWLINE_xXMajor surgery, open biopsy or significant traumatic injury within 4 weeks of first dose of study drugXx_NEWLINE_xXPatients must not have experienced any major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to registration, or be anticipated to need a major surgical procedure during the course of the study; NOTE: the exception is craniotomy; patients with brain tumors who have undergone craniotomy or intracranial biopsy must be cleared by their neurosurgeon to participate at the time of registrationXx_NEWLINE_xXInvasive procedures defined as follows:\r\n* Major surgical procedure, open biopsy or significant traumatic injury within 28 days prior to day 1 therapy\r\n* Brain biopsy within 28 days prior to day 1 of therapy (wounds must be fully healed from brain biopsies performed more than 28 days prior to day 1 of therapy)\r\n* Anticipation of need for major surgical procedures during the course of the study\r\n* Core biopsy within 7 days prior to day 1 of therapyXx_NEWLINE_xXMajor surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to registration (with the exception of craniotomy)Xx_NEWLINE_xXPatients who have had a major surgery or significant traumatic injury within 4 weeks of start of study drug,Xx_NEWLINE_xXFor patients who have had a major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to enrollment, or anticipate the need for such while on active treatment, may participate and receive bevacizumab at the start of the second or third cycle as they would under standard care; placement of vascular access device is not considered major surgery, but the incision must have healed before initiation of treatmentXx_NEWLINE_xXSerious non-healing wound, ulcer, bone fracture, or have undergone a major surgical procedure, open biopsy, or significant traumatic injury =< 28 days or core biopsy =< 7 days prior to randomizationXx_NEWLINE_xXMajor surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to day 1 or anticipation of need for major surgical procedure during the course of the studyXx_NEWLINE_xXSerious non-healing wound, ulcer, bone fracture, major surgical procedure, open biopsy or significant traumatic injury within 28 days prior to being registered for protocol therapyXx_NEWLINE_xXPatients within 28 days post major surgery (e.g., intra-thoracic, intra-abdominal or intra-pelvic), open biopsy, or significant traumatic injury to avoid wound healing complications; minor procedures and percutaneous biopsies or placement of vascular access device without complications require 48 hours prior to study entryXx_NEWLINE_xXMajor surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to day 1 of treatment or anticipation of need for major surgical procedure during the course of the studyXx_NEWLINE_xXMajor surgical procedure (including craniotomy) or significant traumatic injury less than 28 days or those who receive minor surgical procedures (e.g. core biopsy or fine needle aspiration) within 7 daysXx_NEWLINE_xXMajor surgical procedure, open biopsy, or significant traumatic injury within 28 days before start of day 1 of treatment with FOLFIRIXx_NEWLINE_xXMajor surgical procedure, open biopsy, or significant traumatic injury other than craniotomy within 28 days prior to Day 1, anticipation of need for major surgical procedure during the course of the studyXx_NEWLINE_xXHas had major surgery, open biopsy, or significant traumatic injury within 28 days prior to randomization, or anticipation of the need for major surgery during the course of study treatmentXx_NEWLINE_xXMajor surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to enrollment.Xx_NEWLINE_xXMajor surgery or traumatic injury within 28 days of randomizationXx_NEWLINE_xXMajor surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to starting cediranibXx_NEWLINE_xXMajor surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to day 1 therapyXx_NEWLINE_xXNo major surgery, open biopsy or significant traumatic injury within 4 weeks of start of first doseXx_NEWLINE_xXMajor surgical procedure or significant traumatic injury, radiotherapy, chemotherapy, targeted therapy, hormone therapy, or other anticancer therapy.Xx_NEWLINE_xXMajor surgical procedure or significant traumatic injury, as defined by the site investigator, within 28 days before study registration.Xx_NEWLINE_xXSubjects must have recovered from the effects of major surgery or significant traumatic injury at least 14 days before enrollmentXx_NEWLINE_xXMajor surgical procedure, open biopsy (excluding skin cancer resection), or significant traumatic injury within 14 days of initiating study drug (unless the wound has healed) or anticipation of the need for major surgery during the study.Xx_NEWLINE_xXMajor surgery, open biopsy or significant traumatic injury within 4 weeks of starting therapyXx_NEWLINE_xXMajor surgery or significant traumatic injury < 28 days prior to the first RO6927005 infusion (excluding biopsies) or anticipation of the need for major surgery during study treatmentXx_NEWLINE_xXMajor surgical procedure or significant traumatic injury within 28 days before start of study medicationXx_NEWLINE_xXMajor surgical procedure, open biopsy, or significant traumatic injury within 3 weeks before start of study medicationXx_NEWLINE_xXMajor surgical procedure, open biopsy, or significant traumatic injury within 3 weeks before start of study medicationXx_NEWLINE_xXMajor surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to day 1 of therapyXx_NEWLINE_xXMajor surgical procedure, open biopsy, or significant traumatic injury, within 28 days prior to day 1, anticipation of need for major surgical procedure during the course of the study; (minor surgical procedures, fine needle aspirations or core biopsies within 7 days prior to day 1; bone marrow aspiration +/- biopsy is allowed)Xx_NEWLINE_xXMajor surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 1 or anticipation of need for major surgical procedure during course of studyXx_NEWLINE_xXPatients may not have had a major surgical procedure, open biopsy (excluding skin cancer resection, cutaneous/subcutaneous melanoma metastasis resection or biopsy or vascular access device insertion), or significant traumatic injury within 28 days prior to Day 1, or have an anticipated need for major surgical procedure or a planned elective surgical procedure during the course of the study.Xx_NEWLINE_xXPatients with contraindications to anticoagulation therapy for deep venous thrombosis such as:\r\n* Patients on full treatment dose of anticoagulation such as those patients being treated for pulmonary embolus\r\n* Presence of central nervous system or brain metastases\r\n* Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to day 1\r\n* Anticipation of need for major surgical procedure during the course of the study\r\n* Those patients that develop DVTs during the study will be treated with anticoagulants and in certain cases, will continue on the protocolXx_NEWLINE_xXMajor surgical procedure, open biopsy, or significant traumatic injury less than 4 weeks or those who receive minor surgical procedures (e.g. core biopsy or fine needle aspiration) within 1 week from first dose of first study drug administrationXx_NEWLINE_xXMajor surgical procedure or significant traumatic injury within 28 days prior to day 1 or anticipation of the need for major surgery during the course of study treatmentXx_NEWLINE_xXMajor surgery or significant traumatic injury within 14 days of Cycle 1 Day 1.Xx_NEWLINE_xXMajor surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to the first dose of study treatment or anticipation of need for major surgical procedure during the course of the studyXx_NEWLINE_xXMajor surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to randomization, or anticipation of need for major surgical procedure during the course of the studyXx_NEWLINE_xXHistory of major surgery or traumatic injury =< 28 days prior to registration or other major anticipated procedures requiring general anesthesia during study participationXx_NEWLINE_xXMajor surgical procedure or significant traumatic injury within 4 weeks prior to the first dose of study-drug treatment in Cycle 1, or anticipation of the need for major surgery during the course of study treatmentXx_NEWLINE_xXSignificant traumatic injury within 3 weeks prior to initiation of study treatmentXx_NEWLINE_xXMajor surgery or significant traumatic injury within 4 weeks of first study treatment from which the subject has not fully recoveredXx_NEWLINE_xXMajor surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to the first dose of study treatment or anticipation of need for major surgical procedure during the course of the studyXx_NEWLINE_xXMajor surgical procedure or significant traumatic injury within 28 days prior to\n             randomization or anticipation of the need for major surgery during the course of\n             study treatmentXx_NEWLINE_xXMajor surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to enrollment, or anticipation of need for major surgical procedure during the course of the studyXx_NEWLINE_xXMajor surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 1 of Cycle 1 or abdominal surgery, abdominal interventions or significant abdominal traumatic injury within 60 days prior to Day 1 of Cycle 1Xx_NEWLINE_xXMajor surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to the first dose of study treatment or anticipation of need for major surgical procedure during the course of the studyXx_NEWLINE_xXMajor surgery or significant traumatic injury (or unhealed surgical wounds) occurring within 28 days prior to receiving study drug, or planned surgery requiring general anesthesiaXx_NEWLINE_xXMajor surgical procedure, open biopsy, or significant traumatic injury within 28 days before start of study medicationXx_NEWLINE_xXMajor surgical procedure, open biopsy, or significant traumatic injury or anticipation of need for major surgical procedure during the course of the study; core biopsy or other minor surgical procedure, eg placement of a vascular access device, are excluded from this requirementXx_NEWLINE_xXMajor surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to the first dose of study treatment or anticipation of need for major surgical procedure during the course of the studyXx_NEWLINE_xXMajor surgery or significant traumatic injury within 4 weeks of starting study treatment.Xx_NEWLINE_xXMajor surgical procedure, open biopsy, or significant traumatic injury within 28 days before start of study medicationXx_NEWLINE_xXMajor surgical procedure or significant traumatic injury within 28 days before enrollment or anticipation of the need for major surgery during the course of study treatmentXx_NEWLINE_xXPatients who have undergone major surgery (e.g. intra-thoracic, intra-abdominal or intra-pelvic), open biopsy or significant traumatic injury =< 4 weeks prior to starting study drug, or patients who have had minor procedures, percutaneous biopsies or placement of vascular access device =< 1 week prior to starting study drug, or who have not recovered from side effects of such procedure or injuryXx_NEWLINE_xXHistory of invasive procedures defined as follows:            \r\n* Major surgical procedure, open biopsy, or significant traumatic injury =< 28 days prior to registration\r\n* Anticipation of need for major surgical procedures during the study\r\n* Core biopsy =< 7 days prior to registrationXx_NEWLINE_xXMajor surgical procedure, open biopsy, or significant traumatic injury within 28 days before registrationXx_NEWLINE_xXCraniotomy or any other major surgery, open biopsy, or significant traumatic injury within 4 weeks of enrollmentXx_NEWLINE_xXMajor surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to initiation of treatment (or anticipated need during study)Xx_NEWLINE_xXMajor surgical procedures, or significant traumatic injury =< 14 days prior to registration or anticipation of need for elective or planned major surgical procedure during the course of the studyXx_NEWLINE_xXPatient who has undergone the following invasive procedures: Major surgical procedure, open biopsy or significant traumatic injury < 14 days prior to starting study drug or has not recovered from side effects of such therapy, anticipation of need for invasive surgical procedure during the course of the study, biopsy within 7 days prior to starting study drugXx_NEWLINE_xXMajor surgery or significant traumatic injury (or unhealed surgical wounds) occurring within 28 days prior to receiving study drug, or planned surgery requiring general anesthesiaXx_NEWLINE_xXMajor surgery, open biopsy or significant traumatic injury within 4 weeks of first study drugXx_NEWLINE_xXMajor surgical procedure, open biopsy or significant traumatic injury within 28 days prior to commencing study treatment, or anticipation of need for a major surgical procedure during the course of the study;Xx_NEWLINE_xXPatients with the following invasive procedures:\r\n* Major surgical procedures, open biopsy or significant traumatic injury within 28 days prior to day 1 therapy\r\n* Anticipation of need for major surgical procedures during the course of the study\r\n* Minor surgical procedures, fine needle aspirations or core biopsies within 7 days prior to day 1 of therapy; central venous catheter placements are permitted to be completed 7 or more days prior to day 1 of therapy; however, peripherally inserted central catheter (peripherally inserted central catheter [PICC] or PIC line) may be placed at any time prior to or during therapyXx_NEWLINE_xXA major surgical procedure or significant traumatic injury within 28 days of beginning treatment, or anticipation of the need for major surgery during the course of the study; in addition, if a patient has not yet recovered from prior minor surgery (such as central venous access device or fine needle aspiration biopsy)Xx_NEWLINE_xXSignificant traumatic injury within 4 weeks before Cycle 1, Day 1Xx_NEWLINE_xXPatients with or with anticipation of a non-study related invasive procedure defined as followed: major surgical procedure, open biopsy or significant traumatic injury within 28 days prior to the first date of bevacizumab; major non-study related surgical procedure anticipated during the course of the study; core biopsy within 7 days prior to first date of bevacizumabXx_NEWLINE_xXAny serious non-healing wound, ulcer, bone fracture, major surgical procedure, open biopsy or significant traumatic injury within 28 days prior to starting treatment with bevacizumab; if surgically cleared for chemotherapy on trial, bevacizumab may be delayed as clinically indicated up to 8 weeks after such proceduresXx_NEWLINE_xXMajor surgery, open biopsy or significant traumatic injury within 4 weeks of first study drugXx_NEWLINE_xXPatients who have not recovered from the side effects of a major surgery or significant traumatic injury or patients that may require major surgery during the course of the studyXx_NEWLINE_xXMajor surgery (e.g. intra-thoracic, intra-abdominal or intra-pelvic), open biopsy or significant traumatic injury =< 4 weeks and minor procedures (including percutaneous biopsies, placement of vascular access device, laparoscopy +/- biopsy) =< 1 week prior to starting study treatment; patients who have minor procedure(s) > 1 week prior to starting study treatment and have recovered from side effects of such procedure are eligibleXx_NEWLINE_xXMajor surgical procedure, open biopsy, or significant traumatic injury within 28 days before start of study medication; minor procedures such as diagnostic laparoscopy, percutaneous biopsy and paracentesis within 14 days before start of study medicationXx_NEWLINE_xXUndergone major surgery (e.g. intra-thoracic, intra-abdominal or intra-pelvic), open biopsy or significant traumatic injury =< 28 days prior to study registration, or had minor procedures, percutaneous biopsies or placement of vascular access device =< 7 days prior to study registration, or have not recovered from side effects of such procedure or injuryXx_NEWLINE_xXFull recovery from the effects of any major surgery or significant traumatic injury within 14 days prior to the first dose of study treatmentXx_NEWLINE_xXMajor surgical procedure or significant traumatic injury within 14 days prior to first dose of study drug or anticipation of the need for major surgery during study treatmentXx_NEWLINE_xXNo excess risk of bleeding (any of the following):\r\n* Bleeding diathesis or coagulopathy\r\n* Thrombocytopenia\r\n* Major surgical procedure, open biopsy, or significant traumatic injury within the past 28 days or anticipation of need for major surgical procedure during the course of the study\r\n* Minor surgical procedures, stereotactic biopsy, fine needle aspiration, or core biopsy within the past 7 daysXx_NEWLINE_xXPatients with a history of traumatic brain injury prior to tumor diagnosis are not eligibleXx_NEWLINE_xXSignificant traumatic injury or major surgical procedure within 4 weeks prior to starting study treatmentXx_NEWLINE_xXMajor surgery such as intra-thoracic, intra-abdominal or intra-pelvic (with the exception of craniotomy), open biopsy or significant traumatic injury ? 4 weeks prior to registration, or patients who have had minor procedures, percutaneous biopsies or placement of vascular access device ? 1 week prior to registration, or who have not recovered from side effects of such procedure or injury.Xx_NEWLINE_xXMajor surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to day 1 or anticipation of need for major surgical procedure during the course of the studyXx_NEWLINE_xXMajor surgical procedure or significant traumatic injury within 28 days before start of study medicationXx_NEWLINE_xXMajor surgical procedure, open biopsy, or significant traumatic injury within 28 days before start of study medicationXx_NEWLINE_xXMajor surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 1 of Cycle 1Xx_NEWLINE_xXMajor surgical procedure, traumatic injury, non-healing wound, or peptic ulcer ?28 days prior to randomization.Xx_NEWLINE_xXMajor surgery or significant traumatic injury occurring within 4 weeks before randomizationXx_NEWLINE_xXHistory of traumatic brain injuryXx_NEWLINE_xXCraniotomy or any other major surgery, open biopsy, or significant traumatic injury within 4 weeks of randomizationXx_NEWLINE_xXRecovery from effects of any major surgery or significant traumatic injury at least 28 days before the first dose of study treatmentXx_NEWLINE_xXMajor surgical procedure or significant traumatic injury within 4 weeks prior to first dose of study drug treatment in Cycle 1, or anticipation of the need for major surgery during the course of study treatmentXx_NEWLINE_xXMajor surgical procedure or significant traumatic injury within 6 weeks prior to study registration or not fully recovered from any such procedureXx_NEWLINE_xX